What is the standard of care for metastatic Kidney Cancer according to NCCN guidelines

Standard of Care for Metastatic Kidney Cancer (NCCN Guidelines)

Based on the NCCN Guidelines for Kidney Cancer (Version 1.2026), here's what the current standard of care looks like for metastatic disease:

Treatment Approach Depends on Cancer Type

The NCCN distinguishes between two main types of kidney cancer, which affects treatment recommendations:

For Clear Cell Renal Cell Carcinoma (ccRCC)

First-line treatment options (preferred approaches) include:

• Axitinib + Pembrolizumab (Category 1 - highest level of recommendation)
• Cabozantinib + Nivolumab (Category 1)
• Ipilimumab + Nivolumab (Category 1)
• Lenvatinib + Pembrolizumab (Category 1)

These are combination immunotherapy approaches - meaning they combine drugs that work in different ways to fight cancer. The specific choice depends on your risk category (favorable, intermediate, or poor risk based on prognostic factors).

Other recommended options include:

• Axitinib + Avelumab
• Pazopanib (single agent)
• Sunitinib (single agent)

For Non-Clear Cell RCC (nccRCC)

Treatment typically involves:

• Clinical trials (preferred option)
• Systemic therapy (chemotherapy or targeted drugs)
• Metastasectomy (surgical removal of metastatic tumors) for oligometastatic disease (limited number of tumors)

Beyond First-Line Treatment

If your cancer progresses on initial therapy, the NCCN recommends:

• Clinical trials (preferred)
• Subsequent systemic therapy options
• Metastasectomy or SBRT (stereotactic body radiation therapy) for oligometastatic disease
• Best supportive care to manage symptoms and side effects

Important Surgical Considerations

For patients with metastatic disease, the NCCN notes that cytoreductive nephrectomy (surgical removal of the primary kidney tumor) may be considered for selected patients who:

• Have excellent performance status (able to tolerate treatment well)
• Do NOT have brain metastases
• Don't have large-volume distant metastases or significant sarcomatoid (aggressive cell type) burden

Supportive Care is Essential

The NCCN emphasizes that supportive care remains a cornerstone of treatment for all metastatic kidney cancer patients. This includes:

• Pain management
• Bone-modifying agents (bisphosphonates or denosumab) for bone metastases
• Radiation therapy for symptom relief
• Management of treatment side effects

How Doctors Decide Your Specific Plan

Your oncologist will determine which approach is best for YOU based on:

• Risk stratification (using prognostic models like IMDC Criteria or MSKCC Prognostic Model)
• Your overall health and ability to tolerate treatment
• Specific sites of metastatic disease
• Your preferences and goals of care

Questions to Ask Your Oncology Team

1. What is my risk category (favorable, intermediate, or poor risk), and how was this determined?
2. Which first-line combination therapy do you recommend for me, and why is this the best choice for my specific situation?
3. What are the expected benefits and side effects of the treatment you're recommending?
4. Are there clinical trials available that might be appropriate for my case?
5. If my cancer progresses on this treatment, what are the next options we would consider?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.